Master Alliance Provisions Guide (MAPGuide)

AstraZeneca UK, Ltd-UK Secretary of State for Business, Energy & Industrial Strategy Supply Agreement for AZD1222

  • Term & termination | Termination & withdrawal

9. Remedies & Mitigation of Losses
[…]
9.4 If through any action or intervention by any foreign Government, funder or Third Party to direct, influence, mandate or persuade AstraZeneca, its Affiliates or any of its Subcontractors to take or not take any actions so as to affect the performance hereunder or to affect the supply of Product hereunder (including Delivery in accordance with [REDACTED] and/or the Delivery Schedule) such that supply is prevented, adversely effected, reduced, delayed, interfered with, cancelled, suspended, terminated or otherwise interrupted (a “Contract Interference“), including any action taken pursuant to or in consequence of any order or direction under the US Defense Production Act, then AstraZeneca shall promptly notify Purchaser of such event and circumstance (including the consequences in terms of the anticipated date by when Delivery of Product could be made) and, without prejudice to its other remedies hereunder upon written notice to AstraZeneca, Purchaser may cancel any future deliveries of Product and terminate this Agreement, whereupon the consequences in clause 23 [Termination] shall apply.
[…]

22. Duration and Termination
22.3 Either Party shall be entitled to terminate this Supply Agreement upon written notice to the other Party if (i) an adverse safety signal exists in any population in which the Product is being or has been tested which would be reasonably likely to cause the Product not to have a safety profile suitable for Regulatory Approval in the Territory, or (ii) there is evidence of futility of the Product which would be reasonably likely to cause the Product not to have a safety and efficacy profile suitable for Regulatory Approval in the Territory.